IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10973830 B1

PDFFull Text
Date of Patent:
Apr. 13, 2021

Filed:

Apr. 01, 2019

Substituted quinoxaline dna-pk inhibitors

Applicant:

Vertex Pharmaceuticals Incorporated, Boston, MA (US);

Inventors:

John Patrick Maxwell, Hingham, MA (US);

Paul S. Charifson, Framingham, MA (US);

Qing Tang, Acton, MA (US);

Steven M. Ronkin, Watertown, MA (US);

Katrina Lee Jackson, Cambridge, MA (US);

Albert Charles Pierce, Cambridge, MA (US);

David J. Lauffer, Stow, MA (US);

Pan Li, Lexington, MA (US);

Simon Giroux, Cambridge, MA (US);

Jinwang Xu, Framingham, MA (US);

Kevin Michael Cottrell, Cambridge, MA (US);

Mark A. Morris, Somerville, MA (US);

Nathan D. Waal, Cambridge, MA (US);

John J. Court, Littleton, MA (US);

Wenxin Gu, Concord, MA (US);

Hongbo Deng, Southborough, MA (US);

Assignee:

Vertex Pharmaceuticals Incorporated, Boston, MA (US);

Attorney:

Wolf, Greenfield & Sacks, P.C.

Primary Examiner:

Douglas M Willis

Int. Cl.
CPC ...
A61K 31/498 (2006.01); C07D 241/44 (2006.01); A61K 31/5377 (2006.01); C07D 513/04 (2006.01); A61K 31/506 (2006.01); A61K 31/5386 (2006.01); C07D 241/40 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01); C07D 473/40 (2006.01); C07D 475/00 (2006.01); C07D 487/04 (2006.01); C07D 491/048 (2006.01); C07D 498/08 (2006.01); C07D 413/04 (2006.01); C07D 491/052 (2006.01); C07D 241/42 (2006.01); C07D 271/12 (2006.01); C07D 401/12 (2006.01); C07D 413/14 (2006.01); C07D 491/056 (2006.01); C07D 491/08 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5377 (2013.01); A61K 31/506 (2013.01); A61K 31/5386 (2013.01); C07D 241/40 (2013.01); C07D 241/42 (2013.01); C07D 241/44 (2013.01); C07D 271/12 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 413/04 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 473/40 (2013.01); C07D 475/00 (2013.01); C07D 487/04 (2013.01); C07D 491/048 (2013.01); C07D 491/052 (2013.01); C07D 491/056 (2013.01); C07D 491/08 (2013.01); C07D 498/08 (2013.01); C07D 513/04 (2013.01);
Abstract

The present invention relates to Provided are compounds of Formula (I): wherein R, R, X, Ring A, Ring B, and Ring C are as defined herein. Compounds of Formula (I) are useful as inhibitors of DNA-PK. Also provided are pharmaceutical compositions comprising said compounds and methods of using the compounds and compositions in the treatment of various diseases, conditions, and disorders.

Find Patent Forward Citations

Loading…